TAK-660-403 4+

ERT,INC

    • Free

Screenshots

Description

An app for the TAK-660-403 Protocol. Evaluation of long-term safety of ADYNOVI / ADYNOVATE(Antihaemophilic Factor [Recombinant] PEGylated, rurioctocog alfa pegol) in patients with haemophilia A – An ADYNOVI / ADYNOVATE Post-Authorisation Safety Study (PASS)

What’s New

Version 1.2

- Bug fixes for iOS 17

App Privacy

The developer, ERT,INC, indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy.

Data Not Collected

The developer does not collect any data from this app.

Privacy practices may vary based on, for example, the features you use or your age. Learn More

More By This Developer

OM Pharma BV-2020/09 - EAGLE
Medical
PHA022121-C303
Medical
OM Pharma BV-2020/08 - BEAR
Medical
Janssen ICONIC
Medical
REIMAGINE 2 Study App
Medical
Janssen ADVANCE 2
Medical

You Might Also Like

FitsMind Daily Affirmations
Health & Fitness
myPKFiT
Medical
Relevate: Cycling & Training
Health & Fitness
Preclarus
Health & Fitness
Surf Athlete: Surf Training
Health & Fitness
myTeleDoc
Medical